Phase 1, Febuxostat XR Relative Bioavailability Study
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the relative bioavailability, safety and tolerability following
administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.